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Cholesterol accumulation beneath the retinal pigment epithelium (RPE) cells is supposed to contribute 30 
the pathogenesis of age-related macular degeneration (AMD). Cholesterol efflux genes (APOE and 31 
ABCA1) were identified as risk factors for AMD, although how cholesterol efflux influences 32 
accumulation of this lipid in sub-RPE deposits remains elusive. The 18kDa translocator protein, 33 
TSPO, is a cholesterol-binding protein implicated in mitochondrial cholesterol transport. Here, we 34 
investigate the function of TSPO in cholesterol efflux from the RPE cells. We demonstrate in RPE 35 
cells that TSPO specific ligands promote cholesterol efflux to acceptor (apo)lipoprotein and human 36 
serum, while loss of TSPO resulted in impaired cholesterol efflux. TSPO
-/-
 RPE cells also had 37 
significantly increased production of reactive oxygen species (ROS) and upregulated expression of 38 
proinflammatory cytokines (IL-1β and TNFα). Cholesterol (oxidized LDL) uptake and accumulation 39 
were markedly increased in TSPO
-/-
 RPE cells. Finally, in aged RPE cells, TSPO expression was 40 
reduced and cholesterol efflux impaired. These findings provide a new pharmacological concept to 41 
treat early AMD patients by stimulating cellular cholesterol removal with TSPO specific ligands or by 42 
overexpression of TSPO in RPE cells.  43 
Keywords TSPO, cholesterol efflux, retinal pigment epithelium cell (RPE), age-related macular 44 















Age-related macular degeneration (AMD) is the commonest cause of registered blindness in the 58 
developed world (1). An important clinical feature of AMD is the accumulation of both focal 59 
(Drusen) and diffuse extracellular (basal) deposits in the macula, between the retinal pigment 60 
epithelium (RPE) and the adjacent Bruch's membrane. One current hypothesis is that these deposits 61 
lead to dysfunction and later death of RPE and associated loss of photoreceptors (2). Ageing is 62 
associated with progressive accumulation of lipids within Bruch’s membrane (3). Lipid deposition 63 
causes hydraulic conductivity and macromolecular permeability in Bruch’s membrane, which is 64 
thought to impair retinal metabolism. Histopathological analyses of AMD patients’ eyes have 65 
demonstrated the presence of apolipoproteins, cholesterol and cholesteryl ester deposits underneath 66 
the RPE, implicating abnormal cholesterol transport in the progression of this disease (4). Genome 67 
wide association studies have also implicated that hepatic lipase C (LIPC) and cholesteryl ester 68 
transfer protein (CETP), key genes involved in the metabolism of triglycerides and high-density 69 
lipoproteins (HDL), in the pathogenesis of AMD (5,6). 70 
      Excess cholesterol is removed from peripheral cells by the reverse cholesterol transport (RCT) 71 
pathway, by which HDL return excess cellular cholesterol to the liver for either storage as cholesteryl 72 
ester droplets or for excretion in bile. Cholesterol efflux is the first step in RCT mediated by the 73 
removal of cholesterol by acceptors, such as (apo)lipoproteins. Cholesterol efflux is mediated by 74 
ATP-binding cassette (ABC) transporters, such as ABCA1, ABCG1 and ABCG4 (7). Our previous 75 
work in human macrophages has established that increased mitochondrial cholesterol trafficking, via 76 
the 18kDa translocator protein (TSPO), can enhance expression of key genes encoding proteins 77 
involved in the cholesterol efflux pathway, and facilitate removal of cholesterol by apolipoprotein 78 
acceptors (8). Transfer of cholesterol to mitochondrial sterol 27-hydroxylase (CYP27A1) increases 79 
generation of oxysterol ligands for Liver X receptors, which induce the expression of ABCA1, 80 
ABCG1/4 and ApoE.  81 
      Mitochondrial cholesterol trafficking is thought to involve a complex of proteins including TSPO, 82 
steroidogenic acute regulatory protein (StAR), the voltage dependent anion channel (VDAC) and 83 
possibly the adenine nucleotide channel (ANC), together with putative regulatory proteins (9). The 84 
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TSPO protein, previously called the peripheral-type benzodiazepine receptor, is an 18kDa 85 
transmembrane protein localized in the outer mitochondrial membrane of different tissues. TSPO is 86 
thought to mediate a number of functions, including cholesterol transport, steriodogenesis, 87 
neuroinflammation, prevention of apoptosis, and stress adaption (9).  Global or conditional Tspo 88 
knockout (KO) mouse models have been reported; the KO mice exhibited divergent phenotypes 89 
(embryonic lethal, defect in steroidogenesis, or no effect on steroidogenesis) possibly due to genetic 90 
background differences between strains of those KO mice (10-12).       91 
     The RCT process may be important in the pathogenesis of AMD because of its involvement in 92 
lipid and cholesterol transport from RPE (13). The RPE cells are involved in phagocytosis and 93 
degradation of photoreceptor outer segments (POS), which are thought to be the major source of 94 
excess RPE lipids. Incompletely digested POS lipids accumulate as autofluorescent lipid-protein 95 
aggregates called lipofuscin in RPE. Retinoid metabolites, such as bis-retinoids, also contribute to the 96 
formation of lipofuscin (14).  About 20% of RPE cell volume is occupied by lipofuscin by the age of 97 
80 years (15). Notably, the lipofuscin fluorophore A2E blocks cholesterol efflux, resulting in the 98 
accumulation of both free cholesterol and cholesteryl esters in RPE cells (14). Further, RPE cells have 99 
been shown to express ABCA1, scavenger receptor BI (SR-BI), apolipoprotein A-I (ApoA-I), and 100 
apolipoprotein E (ApoE), which participate in the RCT process (16); ABCA1 and ApoE are also 101 
associated with susceptibility to AMD (6, 17). ApoE is synthesized and secreted by RPE cells in 102 
considerable amounts comparable to those in the liver and brain, the two most abundant biological 103 
synthetic sources of ApoE (18). ApoE and ApoA-I proteins were detected in drusen and have been 104 
implicated in aprolipoprotein-mediated RCT in lipid trafficking and in facilitating the efflux of lipids 105 
from the RPE, and their transit across Bruch’s membrane to the choroidal vasculature (19). 106 
      There have been no previous studies investigating the function of the mitochondrial cholesterol 107 
trafficking protein, TSPO, in RPE cells. In this study, we found TSPO to be highly expressed in 108 
human RPE (ARPE-19 cell line) and mouse RPE cells. We also found TSPO ligands significantly 109 
increased cholesterol efflux to ApoE, ApoA-I and HDL from RPE cells. When TSPO was deleted in 110 
RPE cells, TSPO-specific ligand treatment could not increase cholesterol efflux. Aged mouse RPE 111 
cells had significantly decreased Tspo expression and impaired cholesterol efflux. Our observations 112 
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demonstrated that TSPO is involved in regulating cholesterol efflux from RPE cells, suggesting TSPO 113 




TSPO ligands increased cholesterol efflux from RPE cells 117 
Previously reports showed that TSPO, a mitochondrial outer membrane protein, is expressed in 118 
fibroblasts, macrophages, microglia and astrocytes (8, 20-25). We examined TSPO expression in 119 
ARPE-19 cells using a rabbit monoclonal antibody and found TSPO to be present and localized to 120 
mitochondria (Fig. 1). Initially, human ARPE-19 cells were treated with a range of TSPO ligands at 121 
different concentrations (2.5 to 30 μM), compared with the vehicle control, to determine the highest 122 
concentration that does not significantly affect the viability of ARPE-19 cells over 24 hours treatment. 123 
The suitable concentration of each ligand was identified as FGIN-1-27 (10 μM), XBD173 (25 μM) 124 
and Etifoxine (20 μM) respectively (Supplementary Material, Fig. S1).  125 
     Previous reports demonstrated that TSPO regulated cholesterol efflux in fibroblast and 126 
macrophage cells (8, 21). We treated ARPE-19 cells with TSPO specific ligands for 24 hours and 127 
found that FGIN-1-27 and XBD173 significantly increased cholesterol efflux to apoE, apoA-I, HDL, 128 
and human serum (HS), and Etifoxine significantly increased cholesterol efflux to HDL and HS (Fig. 129 
2).  130 
 131 
Ligands of TSPO decreased lipogenesis in RPE cells 132 
We investigated whether treatment of TSPO ligand affected lipogenesis in ARPE-19 cells by 133 
measuring the syntheses of phospholipid, triacylglycerol, cholesteryl and fatty acid. We found 134 
significantly reduced incorporation of [
14
C]acetate into phospholipid by 30% in FGIN-1-27 treated 135 
cells and by 36% in XBD173 treated cells. Incorporation of [
14
C]acetate  into free cholesterol pools 136 
was also significantly decreased by 35% in FGIN-1-27 treated cells and by  31.52% in XBD173 137 
treated cells, compared with the vehicle control (Fig. 3A, B). By contrast, there was no significant 138 
difference when incorporation of [
14
C]acetate into triglycerides, fatty acid and cholesterol ester pools 139 
between ligand-treated and control cells were compared (Fig. 3A and B). Etifoxine-treated ARPE-19 140 
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cells exhibited significant reduction by 57.42% in incorporation of [
14
C]acetate into the free 141 
cholesterol pool compared with the vehicle control; the other examined lipid pools showed no 142 
significant changes for the same comparison (Fig. 3C).  We also measured total cholesterol mass and 143 
phospholipids in control and ligand treated ARPE-19 cells and found significant reduction in total 144 
cholesterol by 35.49%, 32.51% and 23.61% in  FGIN-1-27, XBD173 and Etifoxine treated cells, 145 
respectively (Fig. 3D) and in phospholipid contents by 29.18% and 9.93% in FGN1-27 and XBD173 146 
treated cells respectively (Fig. 3E).  147 
 148 
Ligands of TSPO increased gene expression of proteins involved in cholesterol transport and 149 
metabolism in RPE cells 150 
Since treatment with TSPO ligands influenced cholesterol efflux (Fig. 2), we examined expression of 151 
genes involved in cholesterol homeostasis in ARPE-19 cells that were treated with FGIN-1-27 152 
(10µM), XBD173 (25 µM) or Etifoxine (20 µM) for 24 hours. The mRNA expression levels of these 153 
genes relative to housing keeping gene GAPDH were shown in Supplementary Material, Fig. S2A. 154 
FGIN-1-27 significantly upregulated the expression of NR1H3 (encoding to liver X receptor alpha 155 
protein, LXRα), ABCA1, ABCG1 and CYP27A1 but not CYP46A1 (Supplementary Material, Fig. 156 
S2A), while Etifoxine notably enhanced the expression of LXRα, ABCA1, ABCG1 and CYP46A1 157 
except CYP27A1 (Supplementary Material, Fig. S2A). XBD173 significantly increased expression of 158 
all examined genes when compared to the vehicle controls (Supplementary Material, Fig. S2A). We 159 
also assessed protein levels of LXRα, ABCG1, ABCA1, CYP27A1 and CYP46A1 in ARPE-160 
19 treated with TSPO ligands, by Western blotting (Supplementary Material, Fig. S2B). FGIN-161 
1-27 treatment resulted in significant increases of LXRα, ABCG1 and ABCA1 proteins, 162 
compared with the vehicle controls, but the trend towards increased expression of CYP27A1 163 
and CYP46A1 proved non-significant (Supplementary Material, Fig. S2C). Etifoxine treatment 164 
caused notable increases in expression of ABCG1 and CYP46A1 protein, but no significant 165 
increases in LXRα, ABCA1and CYP27A1 proteins were observed, compared with the 166 
vehicle controls (Supplementary Material, Fig. S2C). Incubation with XBD173 significantly 167 
7 
 
increased the levels of LXRα, ABCG1, CYP27A1 and CYP46A1 proteins, but did not 168 
significantly alter the levels of ABCA1 protein (Supplementary Material, Fig. S2C).  169 
 170 
Knockout of TSPO in RPE cells using the CRISPER/Cas9 engineering system 171 
Human TSPO gene contains four exons with exon 1 untranslated (Fig. 4A). To delete TSPO, we 172 
followed the protocol of the CRISPR/Cas9 system and designed a guide RNA (gRNA) having 173 
sequence complementary to 18 nucleotides (c.87_104) of TSPO exon 2 (Fig. 4A). ARPE-19 cells 174 
were transfected with the gRNA construct and the Cas9 expression plasmid. Nine colonies were 175 
derived from G418 transient selection. Two colonies, named KO1 and KO2, with loss of TSPO were 176 
confirmed by Western blotting using a TSPO-specific antibody (Fig. 4B). Immunocytochemistry 177 
further confirmed TSPO was absent from KO1 and KO2 cells (Fig. 4C). We used Sanger Sequencing 178 
to find that KO1 had an insertion of 82 bp (cc.101_102ins82.) and KO2 contained a deletion of 8 bp 179 
(c.96_103del8) in the target region of exon 2 (Fig. 4A).  The deletion/insertion mutations resulted in 180 
frame-shift reading with truncated peptides (Supplementary Material, Fig. S3).  181 
 182 
Increased lipid accumulation in TSPO knockout RPE cells 183 
Treatment with TSPO specific ligands enhanced cholesterol efflux in ARPE-19 cells (Fig. 2). 184 
However, when TSPO was deleted, the knockout cells had no significant change in [
3
H]cholesterol 185 
efflux to apoE, apoA-I, HDL, or human serum after treatment with FGIN-1-27, XBD173 or Etifoxine 186 
(Supplementary Material, Fig. S4). We therefore investigated whether loss of TSPO in APRE-19 cells 187 
cause lipid accumulation. When wildtype and TSPO
-/-
 cells were incubated with DiI-OxLDL for 24 188 
hours we found intracellular OxLDL were significantly increased in TSPO
-/-
 cells by 39% (p<0.01) 189 
compared to wildtype cells (Fig. 5A, B). We also confirmed significant increase of OxLDL 190 
accumulation in TSPO deleted RPE cells using fluorescence-activated cell sorting assay (Fig. 5C) .We 191 
determined whether the increase of OxLDL accumulation was also related oxLDL uptake in TSPO
-/-
 192 
cells, we fed both wildtype and TSPO
-/-
 cells with DiI-OxLDL for 4 hours and assessed intracellular 193 
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oxLDL by confocal imaging and FACS assay. We found that uptake of OxLDL was significantly 194 
increased by 34% in TSPO deleted cells (Fig. 5D, E, F).    195 
      Previous data showed uptake of LDL and OxLDL by rodent RPE cells occurs primarily via LDL 196 
receptor (LDLR) (26), which is expressed in both rodent and human RPE cells (26, 27). We used 197 
qRT-PCR and Western blotting to assess the level of LDLR in wildtype and TSPO deleted cells 198 
loaded with OxLDL. The LDLR mRNA level in TSPO
-/-
 cells incubated with oxLDL for 4 h and 24 h 199 
was significantly increased by 2341 fold and 1501 fold, respectively, when compared to that of 200 
wildtype cells (Fig. 6A, C). Expression of LDLR protein also increased significantly in TSPO
-/-
 cells 201 
when compared to wildtype cells (Fig. 6B, D).  Intracellular OxLDL cause increased oxidative stress, 202 
promoting the production of inflammatory cytokines, IL-1β and TNFα, that enhance LDLR 203 
expression (28-30). We therefore measured reactive oxygen species (ROS) production in both 204 
wildtype and TSPO
-/-
 RPE cells cultured in serum-free medium or in serum-free medium with 205 
OxLDL. When cultured in serum-free medium, TSPO
-/-
 cells produced significantly higher level of 206 
ROS at 4 and 24 hours by 39% and 52% respectively (Fig. 7A, B), consistent with early report that 207 
deletion of TSPO increased ROS production in steroidogenic cells (31). Both wildtype and TSPO-208 
deleted RPE cells incubated with OxLDL had marked increase of ROS production at 4 and 24 h when 209 
compared to cells cultured in serum-free medium, indicating oxLDL promoted ROS production. In 210 
the presence of OxLDL, TSPO
-/-
 cells also had significant increase of ROS production when 211 
compared to wildtype RPE cells at 4 and 24 h by 64% and 58% respectively (Fig. 7A, B).  212 
      We also measured the secretion of IL-1β and TNFα into the media above wildtype and TSPO-213 
deleted cells by enzyme-linked immunosorbent assay (ELISA). When cultured in serum-free medium, 214 
TSPO
-/-
 cells exhibited a trend towards increased output of IL-1β at 4 and 24 hours though there was 215 
no significant difference compared to wildtype cells. However, TNFα levels were increased in the 216 
media above TSPO
-/-
 cells by 37%, with a significant difference noted from the wildtype control at 24 217 
hours (Fig. 7C, D).  Levels of both IL-1β and TNFα were markedly higher in TSPO-/- cells compared 218 
to wiltype cells when incubated with oxLDL at 4 and 24 h (Fig. 7C, D). Further, when wildtype and 219 
TSPO
-/-
 RPE cells were treated with IL-1β (10ng/ml) or TNFα (50ng/ml) for 4 hours, the level of 220 
LDLR protein was significantly, if modestly, increased in TSPO-deleted cells; when treated for 24 221 
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hours with these cytokines, LDLR protein levels were significantly increased in both wildtype and 222 
TSPO
-/-
 cells (Supplementary Materials, Fig. S5).        223 
 224 
Reduced TSPO expression and impaired cholesterol efflux in aged mouse RPE cells  225 
Wang et al (2015) examined TSPO localization in developmental and young adult mouse retina and 226 
showed TSPO was localized in the developing and migratory microglia at P0, P3 and P7, while the 227 
localization in microglia disappeared at P14. At P28 (young adult), TSPO signal was detected only in 228 
retinal blood vessels and not in any other retinal cells, however TSPO protein was gradually increased 229 
during retinal development with significant high level in young adult retina (25). We performed 230 
immunostaining to detect TSPO expression in the retinas of adult mice (3 months old) and found a 231 
marked strong signal in RPE cell layer, and quite a strong signal presented in the ganglion cell layer 232 
(Fig. 8A, B). We also detected TSPO immunopositivity in the choroid, possibly in the choroid 233 
vessels.  We quantified the expression of Tspo mRNA and protein in mouse retina and RPE/choroid: 234 
Tspo mRNA level in RPE/choroid was 20.7 fold higher than that in the retina, TSPO protein level in 235 
RPE/choroid was 16.7 fold higher than that in the retina (Fig. 8C-E).  236 
      We further investigated TSPO expression in aged mouse RPE and retina: TSPO was significantly 237 
decreased by 58.67% at mRNA level and by 24.46% at protein level in 20-month old mouse RPE 238 
cells when compared to that of 3-month old RPE cells (Fig. 9A-C). Expression of the cholesterol 239 
transporter genes, Abca1 and particularly Abcg1, in aged RPE was also significantly decreased 240 
(Supplementary Material, Fig. S6A). In aged mouse retina, we also detected significantly declined 241 
expression of Tspo, Abca1 and Abcg1 (Supplementary Material, Fig. S6B).     242 
      The total cholesterol mass was measured in 3-month and 20-month old mouse RPE and that the 243 
cholesterol mass of 20-month old RPE was significantly higher than that of 3 moth-old RPE/choroid 244 
(Fig. 9D). We therefore investigated whether the increase of total cholesterol in aged RPE is partially 245 
due to a defect in cholesterol efflux. We observed that the percentage of [
3
H]cholesterol efflux to 246 
apoE, apoA-I, HDL, or human serum was significantly decreased in 20-months old RPE when 247 





Extensive clinical studies show abnormal cholesterol accumulation in drusen of AMD patients, 251 
implicating dysregulated cholesterol homeostasis (32). Experimental research has demonstrated that 252 
impaired cholesterol efflux might contribute to the pathogenesis of AMD (15,33). However the 253 
underlying mechanisms are not fully understood.  The present study demonstrated that TSPO ligands 254 
enhance cholesterol efflux in RPE cells. Deletion of TSPO prevented modulation on cholesterol efflux 255 
by TSPO ligands and resulted in markedly increased cholesterol (OxLDL) uptake and accumulation in 256 
TSPO
-/-
 RPE cells. Aged mice had significant decrease in retinal and RPE expression of TSPO and 257 
defective cholesterol efflux in aged primary RPE cells. 258 
      TSPO is an outer mitochondrial membrane (OMM) protein with five transmembrane (TM) helixes 259 
and can bind cholesterol at a high affinity through its C-terminal cholesterol recognition amino acid 260 
consensus (CRAC) motif to transport cholesterol to the inner mitochondrial membrane (IMM) (34, 261 
35).  TSPO can also bind different ligands, which promote cholesterol movement from OMM to 262 
IMM, where cholesterol is converted into pregnenolone by CYP11A1 in steroidogenic tissues or into 263 
oxyterols (27-hydroxycholesterol and 5-cholestanoic acid) by CYP27A1 in macrophage and other cell 264 
types (34). Oxysterols can activate a nuclear transcription factor, liver X receptor (LXRα/β), thereby 265 
upregulating the transcription of ABCA1, ABCG1 and ABCG4, which promote cholesterol efflux. In 266 
ARPE-19 cells, TSPO specific-ligands enhanced the efflux of cholesterol to ApoA-I, apoE and HDL 267 
(Fig. 2) and markedly decreased the total cholesterol level, and the biogenesis of free cholesterol (Fig. 268 
3). Equally, TSPO ligand treatment significantly increased expression of ABCA1, ABCG1 and LXRα 269 
(Supplementary Material, Fig. S2). CYP27A1 was localised in human RPE (27) and its expression 270 
was significantly increased in RPE cells exposed to TSPO specific ligands FGIN-1-27 or XBD173 271 
(Supplementary Materials, Fig. 3). Our data suggested TSPO has similar function in cholesterol efflux 272 
in RPE cells possibly through oxyterol activated LXR-mediated upregulation of cholesterol 273 
transporter genes and down-regulation of cholesterol biosynthesis.   274 
      Apolipoprotein-containing lipoproteins accumulate and become oxidized in drusen (36). 275 
Apolipoprotein B100 (apoB100) is the major apolipoprotein of LDL, and oxidized apoB100 and 276 
OxLDL localized in drusen (37). Early data showed OxLDL was internalized by RPE cells, causing a 277 
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defect in outer segment phagocytosis and induced apoptosis (37-40). Recent data demonstrated 278 
OxLDL triggered the alternative complement pathway by decreasing complement regulator CD59 and 279 
increasing the formation of membrane attack complexes (MACs) in RPE cells (41,42). Our 280 
experiments indicated that deletion of TSPO enhance OxLDL uptake and accumulation in RPE cells 281 
(Fig. 5), which may contribute to abnormal outer segment phagocytosis and dysfunction of the 282 
alternative complement system. Certainly, loss of TSPO caused increased oxidative stress in RPE 283 
cells by producing higher level of ROS (Fig. 7A, B) and secretion of IL-1β and TNFα levels was 284 
markedly increased in OxLDL-treated TSPO
-/-
 RPE cells (Fig. 7C, D). When ARPE-19 cells were 285 
exposed to IL-1β or TNFα, the expression of LDLR was significantly upregulated (Supplementary 286 
Material, Fig. S5), which promotes OxLDL uptake. ROS also can oxidatively modify macromolecules 287 
such as DNA, protein and lipid and lead to dysfunction of RPE cells. Together, these data suggest that 288 
loss of TSPO contributes to both dysregulated cholesterol metabolism and inflammation, and may 289 
play a central in the pathogenesis of AMD. 290 
      TSPO is upregulated in activated microglial cells of different neurodegenerative diseases and 291 
recognized as a biomarker for early diagnosis and disease progression (43); TSPO expression was 292 
significantly increased at mRNA and protein level in retinal microglial cells by LPS-induced 293 
inflammation (25, 44). TSPO was also strongly upregulated in retinal microglia in models of retinal 294 
injury and degeneration (25, 44). Knockdown of TSPO significantly increased ROS production and 295 
TNFα secretion in microglial cells (BV2) in response to LPS challenge; there was no significant 296 
increase of ROS production and TNFα expression in knockdown cells without LPS-activation, 297 
possibly due to only 30-40% TSPO depletion (44). In this study, TSPO knockout RPE cells had 298 
significant increase in the production of ROS and in secretion of IL-1β and TNFα (Fig. 7C,D). TSPO 299 
ligand (PK-11195 and Ro5-4864) treatment significantly decreased ROS production and TNFα 300 
secretion in BV2 cells; intravitreal treatment with a TSPO ligand (TTN) inhibited LPS-induced retinal 301 
inflammatory reaction by reducing retinal lipid peroxidation and TNFα protein level (25). Treatment 302 
with another TSPO ligand, XBD173, reduced expression of pro-inflammatory genes and prevented 303 
photoreceptor cell death in light-induced retinal degeneration (45). We also found treatment with 304 
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TSPO ligands significantly down-regulated expression of pro-inflammatory cytokines in ARPE-19 305 
cells (data not shown).   306 
      Previous reports showed that TSPO was localized to retinal microglia and inner retinal blood 307 
vessels (25, 44). We found very strong TSPO signal in three-month old mouse RPE cells, less strong 308 
signal in the choroid and some weak signals in the inner and outer plexiform layers (possibly the 309 
microglia); we also found quite strong signals in ganglion cells (Fig. 8A, B). Ishikawa et al reported 310 
that increased pressure could upregulate TSPO expression in rat ganglion cells; TSPO was 311 
undetectable at 10 mmHg and significantly increased in ganglion cells at 35 mmHg and 75 mmHg 312 
respectively (46). The difference of immunolocalization of TSPO in retina was possibly due to 313 
different approaches for preparing immunostaining samples or immunodetection methods. We used 314 
qRT-PCR and Western blotting to confirmed higher level of TSPO expression RPE/choroid when 315 
compared to the retina (Fig. 8C-E).   During retinal development, Wang et al detected highest TSPO 316 
mRNA level in postnatal 0 (P0) retina, then significantly lower but steadily increased in postnatal age 317 
(P0-P28), TSPO protein was also steadily increased in postnatal age (P0-P28) (25). However, another 318 
group found TSPO mRNA was at highest level in P3 retina then continuously decreased to low levels 319 
in adult (P60) retinas (44). We found that TSPO expression was markedly decreased in aged mouse 320 
retina and RPE/choroid (Fig. 9A-C, Supplementary Material, Fig. S6B).  Aged mouse RPE cells had 321 
lower level of cholesterol efflux and higher level of total cholesterol (Fig. 9D, E), which may be in 322 
part due to decreased TSPO, which appears to regulate cholesterol efflux in the RPE cells (Fig.2 and 323 
Supplementary Material, Fig. S4).      324 
      Prevention of AMD progression is a priority in the long-term care of patients with early stage 325 
disease. In pursuit of this objective several strategies are currently being investigated including high-326 
dose lipid lowering therapy (47) and laser-based interventions (48). Targeting the cholesterol efflux 327 
pathway in order to ameliorate and/or reverse subretinal accumulation of lipid with associated RPE 328 
dysfunction warrants further investigation. The availability of an approved TPSO ligand therapeutic 329 
paves the way for translation to clinical trial. If safety and efficacy are demonstrated this novel 330 
approach would usefully impact a key pathway likely to be involved in the complex process of 331 
progression from early to late stage AMD. How modification of the TPSO pathway using a 332 
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biochemical approach or AAV-gene therapeutic might supplant or supplement other tools in reducing 333 
the burden of AMD-related visual loss requires further study. Further we plan to investigate the role 334 
of this pathway in other conditions which show sub-retinal deposits resembling AMD for example 335 
late-onset retinal degeneration (49) and Sorsby fundus dystrophy (50).  336 
 337 
Materials and methods 338 
Reagents 339 
Cell culture medium, trysin, and penicillin/streptomycin were purchased from Lonza, UK. 340 
Lipofectamine 2000 Transfection reagent, T-PER Tissue Protein Extraction, CellTracker™ Orange 341 
CMTMR Dye, and Amplex® Red Cholesterol Assay were from Thermo Fisher Scientific, UK. ApoE, 342 
ApoA-I, HDL and LDL were purchased from the Athens Research (USA). LDL, Oxidized LDL 343 
(oxLDL) and fluorescence-labelled oxidized LDL (Dil-acLDL) were purchased from Alfa Aesar, UK. 344 
Recombinant human TNFα, IL-Iβ and human TNF-α and IL-Iβ ELISA Development Kit were from 345 
Peprotech, UK. Radiochemicals ([
3
H]cholesterol and  [
14
C]acetic acid) and Scintilant were provided 346 
by the ICN Biologicals. G418, TLC plate, phospholipids Assay, dispase II protease, Tri Reagent, and 347 
tetrazolium salt were purchased from Sigma–Aldrich. Cas9 vector and gRNA vector were obtained 348 
from Addgene, USA. Antibodies, TSPO (ab109497), CYP27A1 (Ab64889), LXRα (ab176323), 349 
ABCA1 (ab7360), ABCG1 (ab52617),  Alexa fluo 594 conjugated secondary antibody, and GAPDH 350 
antibody were from Abcam. CYP46A1 and LDLR antibodies were from Novus Biologicals, UK. 351 
Donkey anti mouse and donkey anti rabbit secondary antibodies were from Santa Cruz, UK. Mito 352 
ViewTM Green was from Biotium, UK. 353 
Cell culture 354 
The human retinal pigment epithelium cell line (ARPE-19, ATCC® CRL-2302™) were maintained in 355 
DMEM/F-12 medium supplemented with 10% (v/v) fetal bovine serum (FBS),  356 
penicillin/streptomycin (50 µg/ml and 50 IU/ml respectively) and 0.26% Sodium bicarbonate. For 357 









 cells per well respectively. 359 
Cells viability 360 
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The ARPE-19 cells (1×10
5 
cells/well) were cultured in 48-well plates. The cells were treated with 361 
different TSPO ligands (FGIN-1-27, XBD173, Etifoxine) in serum free media and incubated for 24 362 
hours. Then the cells were washed with PBS and treated with serum-free medium containing 0.4 363 
mg/mL MTT[3-(4, 5-dimethylthiazol-2-l) -2,5-diphenyltetrazolium bromide]. During this period of 364 
treatment, mitochondrial cytosolic dehydrogenases of living cells reduced the yellow tetrazolium salt 365 
(MTT) to a purple formazan dye suitable for spectrophotometric detection. After 2 hours the MTT 366 
solution was aspirated and dimethylsulfoxide (0.2 mL/well) was added to dissolve the formazan. The 367 
plate was shaken for 10 minutes and then was read on a micro plate reader (EPOCH) at 575nm for 368 
densities. The absorbance was normalised to untreated cells representing 100% cell viability.  369 
Measurement of [
3
H]cholesterol efflux  370 
Efflux of [
3
H]cholesterol to apoAI, apoE, HDL and human serum (HS) in RPE cells was determined 371 
following previous description (8). Briefly, cells were seeded on 12 well plates and labelled with 372 
[
3
H]cholesterol for 24 hours with 2% BSA in serum free culture media. Efflux was initiated by the 373 
addition of serum-free DMEM/F12 containing human apoAI (10 µg/ml), apoE (10 µg/ml), HDL (20 374 
µg/ml) or human serum (1%, v/v) and in the presence or absence TSPO ligands, and cultured for 24 375 
hours. Cholesterol efflux was then calculated as an expression of percentage of cholesterol efflux to 376 
each of the acceptors as follows: % efflux = (disintegrations per minute (DPM) media/DPM Media + 377 
DPM Cells) × 100.  378 
Lipid analysis  379 
Incorporation of [
14
C]acetic acid (1 µCi/ml) into fatty acid, phospholipid,  cholesterol, cholesteryl 380 
ester and triacylglycerol pools was measured after incubation in the presence or absence of TSPO 381 
ligands for 24 hours, as previously described (9,10). Cellular lipids were extracted using hexane: 382 
isopropanol (3:2, v/v), dried under nitrogen gas and resuspended in isopropanol, before separation by 383 
thin-layer  chromatography (TLC) using mobile phase-I buffer (chloroform, methanol and water, 384 
60:30:5, v/v/v) and mobile phase-II buffer (hexane, diethyl ether andacetic acid, 80:20:1.5, v/v/v. 385 
Lipids were identified by co-migration with authentic standards and incorporation of radiolabel 386 
assessed by scintillation counting. Mass of total cellular cholesterol and phospholipids in ARPE-19 387 
cells was measured using an Amplex® Red Cholesterol Assay Kit (Thermo Fisher scientific) 388 
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according to the manufacturer’s guidance. Total cholesterol mass of mouse RPE/choroid was  389 
measured similarly.  390 
Measurement of reactive oxygen species (ROS) 391 
Wildtype and TSPO
-/-
 ARPE-19 cells were incubated with OxLDL (200µg/ml) for 4 h or 24 hours. To 392 
detect intracellular ROS, cells were incubated for 30 minutes with the fluorescence dye carboxy-2′,7′-393 
dichloro-dihydro- fluorescein diacetate (DCFHDA, Sigma, UK). The fluorescence signals were 394 
measured at 485 nm (excitation) and 520 nm (emission) using FluoStar Optima MBG-Labtech 395 
microplate reader. The ROS level was represented as fluorescence of treated cells) / fluorescence of 396 
untreated cells. 397 
Enzyme-linked immunosorbent assay (ELISA) 398 
The cells were treated with oxLDL (200µg/ml) for 4 or 24hours. The levels of IL-1β and TNF-α  in 399 
culture medium were quantified by ELISA with human TNF-α and IL-1β kits (Peprotech, UK) 400 
following the manufacturer’s protocols.  401 
Uptake of oxidized LDL by RPE cells 402 
Fluorescence-labelled DiI-oxidized LDL (DiI-OxLDL) was purchased from Alfa Aesar, UK. ARPE-403 
19 cells were seeded in 6-well plates and treated with DiI-OxLDL (20µg/ml) for 4 or 24 hours. The 404 
treated cells were washed five times with PBS and fixed with 4% PFA for 10 min at room 405 
temperature then mounted with Vectashield medium with DAPI (Vector Lab Ltd. Peterborough, UK). 406 
The intracellular fluorescence-labelled DiI-OxLDL was visualized by LSM 510 Zeiss confocal 407 
microscope (Zeiss) and quantified using Image J.  408 
Flow cytometry  409 
The ARPE-19 cells were treated with DiI–labeled oxidized LDL (20µg/ml) for 4 hours and 24hrs. 410 
Then the cells were washed 3 times with PBS and twice with PBS containing BSA (2 mg/ml). The 411 
cells were collected by detachment in trypsin, resuspended with complete medium and centrifuged at 412 
1000 rpm for 5 minuties and washed two times with PBS. The cells were analysed by flow cytometry 413 
(10,000 events; Excitation, 514 nm; Emission; 550 nm) using a FACSCalibur BD Immunocytometry 414 
Systems. The data were analyzed by FlowJo software (Treestar Inc). 415 
Knockout of TSPO in ARPE-19 cells  416 
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The clustered regularly interspaced short palindromic repeats (CRISPR) system was employed to 417 
knockout the TSPO gene from ARPE-19 cells. The CRISP primers were designed using 418 
https://benchling.com website to targeting exon 2 of TSPO gene (Accession: NC_018933). The 419 
CRISP Oligos were extended using Phusion DNA polymerase (New England Biolab, UK) and ligated 420 
into linearized gRNA vector (Addgene 41824) using Gibson assembly to generate a CRISP TSPO-421 
gRNA construct, which was confirmed by sequencing. The CRISP TSPO-gRNA construct and Cas9 422 
plasmid (Addgene 41815) were transfected into ARPE-19 cells. TSPO knockout colonies were 423 
verified by Western blotting, Sanger sequencing and immunocytochemistry. 424 
Isolation of primary retinal pigment epithelium (RPE) cells from mouse eyes  425 
Eyes from 3-month and 20-month old mice were washed three times in PBS then washed twice in 426 
DMEM F-12 medium. The eyes were transferred into HBSS solution and a circular incision was made 427 
around the ora serrata of each eye. The lens and retina were removed, the RPE/choroid/sclera was 428 
incubated with 2% dispase solution (w/v) in complete medium for 45 minutes at 37°C with 5 % CO2. 429 
The RPE/choroid/sclera was washed with PBS twice then incubated with trypsin-EDTA at 37°C for 430 
15-20 minutes. After incubation the RPE/choroid/sclera was vigorously shaken to detach the RPE 431 
cells. The detached RPE cells were cultured in DMEM F-12 medium until they reached confluent.  432 
Quantitative real-time polymerase chain reaction (qRT-PCR)  433 
Total RNA was extracted from ARPE-19 cells, mouse RPE/choroid, or mouse retinas using Tri 434 
Reagent (Sigma, UK) according to the manufacturer’s guidance. The cDNA was synthesised by using 435 
High Capacity cDNA Reverse Transcription Kit with RNAase inhibitor (Applied Biosystems, UK). 436 
The quantification of gene expression was performed by a qRT-PCR assay using a Platinum Syber 437 
Green QAPCR Super Mix-UDG w/ROX kit (Invitrigen, UK) with primers for targeted genes.  438 
Immunocytochemistry and Immunohistology 439 
Wildtype and TSPO-deleted ARPE-19 cells were incubated with mitochondrial dye, MitoView Green 440 
(100nM, Biotium, USA) in culture medium for 30 minutes at 37°C. After multiple washes with PBS, 441 
the cells were fixed with 4% paraformaldehyde and blocked with 2% sheep serum with 2% BSA in 442 
PBS then stained with a primary rabbit monoclonal TSPO antibody (Abcam ab109497, 1:200 443 
dilution) which recognizes human TSPO C-terminal, and with secondary Alexa Fluor 594 secondary 444 
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antibody. In addition, mouse (three-month old) eyes were fixed with 4% paraformaldehyde in PBS 445 
and cryoprotected in Cryomatrix medium (VWR, UK). The eyes were sectioned and mounted on 446 
superfrost slides. The sections were blocked with 2% BSA in PBS and incubated with primary and 447 
secondary antibodies. Images were captured using a LSM 510 confocal microscope (Zeiss). 448 
Western blotting 449 
Cell lysates were prepared in Radio-Immuno Precipitation Assay (RIPA) cell lysis buffer containing 450 
25mM Tris-HCl pH8, 150mM Sodium Chloride, 1% (w/v) sodium deoxycholate, 1% (v/v) 451 
nonylphenoxypolyethoxylethanol (NP-40), and 0.1% (w/v) sodium dodecyl sulphate supplemented 452 
with Complete™ protease inhibitors (Roche). Mouse retina and RPE/choroid tissues were lysed using 453 
T-PER
TM
 tissue protein extraction reagent (Thermo Fisher Scientific, UK). Proteins were separated by 454 
SDS-PAGE and transferred to nitrocellulose membranes. Target proteins were detected by incubation 455 
with primary (1:2000 for TSPO and GAPDH; 1:200 for ABCA1, 1:1000 for ABCG1, CYP27A1 and 456 
CYP46A1) and secondary (1:10000 dilution) antibodies. The intensity of specific bands was 457 
quantified using Li-cor Odyssey FC and Image Studio software. 458 
Statistical Analysis 459 
Data was analysed by statistical significance using analysis of variance (ANOVA) and a t-test, 460 
followed by appropriate post hoc tests (Bonferroni). As indicated, all data are presented as mean±SD  461 
and collected from three independent experiments. Statistical analysis was performed using Prism 462 
software (version 6.0 from GraphPad Software Inc., San Diego, CA, USA); *p<0.05, **p<0.01 and 463 
***p<0.001, ****p<0.0001. 464 
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Legends to Figures 633 
Figure 1 TSPO localization in ARPE-19 cells. ARPE-19 cells were incubated with MitoView 634 
(mitochondria marker) and fixed with cold methanol, then incubated with anti-TSPO antibody and 635 
secondary antibody. TSPO was cololcalized with MitoView in mitochondria.   636 
 637 
Figure 2 Cholesterol acceptor-mediated cholesterol efflux was measured from ARPE-19 cells. The 638 
cells were treated with TSPO ligand, FGIN-1-27 (10 µM), XBD137 (25 µM) or Etifoxine (20 µM) for 639 
24 hours. The percentage of [
3
H] cholesterol efflux was measured from the medium and the cellular 640 
lipids. Data was presented as means±SD. Every experiment was performed in triplicate and three 641 
independent experiments were carried out. NS: non-significant, *p<0.05, **p<0.01, ****p<0.0001:  642 
 643 
Figure 3 TSPO ligand modulation of lipids phenotypes. A-C Impact of TSPO ligands (Fgin-1-27, 644 
XBD173 and Etifoxine) on nmol incorporation per mg total protein of [
14
C] acetate (1 μCi/ml) into 645 
phospholipid, triacylglycerol, cholesteryl ester, free cholesterol and fatty acid pools compared with 646 
the vehicle control. The incorporation of radiolabel was normalised to mg total cellular protein. The 647 
effect of TSPO ligands on the ARPE-19 total cholesterol (D) and phospholipids mass (E) were 648 
reduced significantly due to expose to TSPO ligands for 24 hours. Values of total cholesterol and 649 
phospholipids from above experiments were normalised based on total cellular protein. Three 650 
independent experiments were performed. **p<0.01, ***p<0.001, ****p<0.0001. 651 
 652 
Figure 4 CRISPR/Cas9 system mediated knockout of TSPO from ARPE-19 cells. (A) Schematic 653 
structure of TSPO gene, the targeting sequence and the protospacer adjacent motif (PAM) were 654 
shown. (B) After transfection with TSPO-CRISPR/Cas9 construct, ARPE-19 colonies were screened 655 
for TSPO protein expression using a monoclonal TSPO antibody. Two TSPO-deleted colonies (KO1 656 
and KO2) were identified by Western blotting. (C) Immunocytochemistry also confirmed the 657 




Figure 5 Significantly increased cholesterol accumulation and uptake in TSPO
-/-
 cells. The wildtype 660 
and TSPO
-/-
 ARPE-19 cells were incubated with DiI-oxLDLa (20µg/ml) for 4 hours or 24 hours. The 661 
intracellular oxLDL was detected by confocal microscopy and also assessed by fluorescence-activated 662 
cell sorting (FACS). (A) Confocal image showing more oxLDL accumulation in TSPO deleted RPE 663 
cells. (B) Quantification of fluorescence signals by using Image J software showing significant 664 
increase of oxLDL accumulation in TSPO
-/-
 cells when compared to wildtype cells. (C) FACS 665 
showing significant increase of fluorescence intensity in TSPO
-/-
 RPE cells when compared to the 666 
wildtype cells exposed to oxLDL for 24 hours (p<0.001). (D) Confocal image showing increased 667 
uptake of oxLDL. (E) Quantification of the increase using Image J software confirming the increase 668 
of uptake by 34% in TSPO knockout cells. (F) FACS showing marked increase of oxLDL uptake in 669 
TSPO-deleted cells (p<0.001). **p<0.01, ***p<0.001. 670 
 671 
Figure 6 The expression of LDLR was quantified after exposure to oxLDL. (A) After 4 hours 672 
incubated with oxLDL, mRNA level of LDLR was increased 2341 fold in TSPO knockout cells 673 
compared to wild type cells as well as protein level also increased significantly (B). Similarly, after 24 674 
hours incubation of oxLDL, LDLR mRNA (C) and protein (D) were significantly increased. Data 675 
were presented as mean±SD. NS: no significance,*p<0.05, **p<0.01, ***p<0.001. 676 
 677 
Figure 7 Significantly increased reactive oxygen species (ROS) and inflammatory cytokines levels in 678 
TSPO-deleted RPE cells. Wildtype (WT) and TSPO knockout (KO) ARPE-19 cells were exposed to 679 
oxLDL (200µg/ml) or vehicle control for 4 or 24 hours. (A) Cellular ROS levels were increased 680 
markedly after treated with oxLDL (4 hours), however in TSPO-deleted cells ROS were remarkably 681 
higher than that of wildtype cells. Similarly, marked increase of ROS also occurred in TSPO knockout 682 
cells after 24 hours exposure to oxLDL (B). The levels of the inflammatory cytokines (IL-1β and 683 
TNFα) were significantly increased TSPO deleted cells after exposure to oxLDL for 4 or 24 hours (C, 684 




Figure 8 TSPO protein in mouse retina and RPE/choroid. Three-month old mouse eye sections were 687 
immunostained with an TSPO antibody for TSPO expression and DAPI for labelling nuclei. (A) 688 
Immunolocalization of TSPO in choroid, retinal pigment epithelium (RPE), outer nuclear layer 689 
(ONL), and inner nuclear layer (INL). Strong TSPO signals were presented in the RPE layer. (B) 690 
TSPO signals detected in ganglial cells layer (GCL). Retina and RPE/choroid (RC) were lysed to 691 
quantify TSPO expression at mRNA and protein levels. Both mRNA (C) and protein (D, E) of TSPO 692 
were significantly higher in RPE/RC than that of the retina. Data were presented as mean±SD. 693 
***p<0.001.  694 
 695 
Figure 9 TSPO expression, total cholesterol and cholesterol efflux in aged mouse RPE. (A) mRNA of 696 
Tspo expression was significantly decreased in 20-month old mouse RPE cells. (B, C)  TSPO protein 697 
in RPE cell derived from 20-month old mice was also significantly decreased. TSPO protein intensity 698 
was normalized to GAPDH. (D) Total cholesterol contents of RPE cells derived from 3-month or 20-699 
month mice were measured and normalized to total protein contents. RPE cells from 20-month old 700 
mice had marked higher level of total cholesterol when compared to RPE cells form 3-month old 701 
mice. (E) RPE cell derived from 3 or 20 months old mice were labelled with 0.5μCi/mL [3H] 702 
cholesterol for 24 hours followed by 24 hours incubation with or without Apo A-I (10μg/ml), HDL 703 
(20μg/ml) and human serum (HS, 1% v/v). After incubation, the percentage of [3H]cholesterol efflux 704 
was measured. RPE cells from aged (20-month old) had significant decrease in cholesterol efflux to 705 
ApoAI, HDL and human serum.  706 
 707 
Abbreviations 708 
ABCA1:  ATP binding cassette subfamily A member 1; ABCG1: ATP binding cassette subfamily G 709 
member 1; AMD: age related macular degeneration; CETP: cholesteryl ester transfer protein; HDL: 710 
high-density lipoprotein; LDL, low-density lipoprotein; LIPC: hepatic lipase C; RPE retinal pigment 711 
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